10-Q: Vicapsys Life Sciences Reports Q1 2024 Results, Cites Going Concern Uncertainty

Vicapsys Life Sciences reports a net loss for Q1 2024 and expresses substantial doubt about its ability to continue as a going concern.

Summary

• Vicapsys Life Sciences, Inc. reported its financial results for the quarter ended March 31, 2024.
• The company experienced a net loss of $327,072 for the quarter.
• There were no revenues reported for the three months ended March 31, 2024 and 2023.
• The company had a working capital deficit of $2,255,754 and an accumulated deficit of $16,627,147 as of March 31, 2024.
• These factors raise substantial doubt about the company's ability to continue as a going concern.
• The company anticipates needing to raise an additional $1 million to sustain base operations during the next 12 months.
• In July 2024, the company entered into a promissory note agreement for $95,000.
• In August 2024, the company entered into a promissory note agreement for $55,000.
• The company's strategy involves developing and commercializing intellectual property rights related to encapsulated products for therapeutic purposes.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to the company's net losses, working capital deficit, accumulated deficit, going concern uncertainty, and defaults on agreements. While the company is seeking funding and pursuing partnerships, the current financial situation raises significant concerns.

Positives

• The company is actively seeking additional funding through debt or equity financings.
• The company continues to develop its intellectual property rights related to encapsulated products.
• The company is pursuing corporate partnerships to advance clinical development and commercialization.

Negatives

• The company experienced a net loss of $327,072 for the three months ended March 31, 2024.
• The company had a working capital deficit of $2,255,754 and an accumulated deficit of $16,627,147 as of March 31, 2024.
• The company states there is substantial doubt about its ability to continue as a going concern.
• The company has defaulted on the pre-sales diligence requirements of the MGH License Agreement and is negotiating an extension.
• The company is in default with the terms of its convertible notes.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company may not be able to obtain additional funding on commercially reasonable terms, or at all.
• Failure to generate revenue or raise funds could cause the company to go out of business.
• The company is in default of the pre-sales diligence requirements of the MGH License Agreement.
• The company is in default with the terms of the convertible notes.
• The company has an ineffective control environment due to a lack of internal resources with expertise to determine entries and disclosures related to some of the company's more complex equity transactions.

Future Outlook

The company anticipates needing to raise an additional $1 million through the issuance of debt or equity securities to sustain base operations during the next 12 months, excluding development work.

Management Comments

• The Company intends to honor the notes and all liabilities as it perseveres in its mission to raise funds for the Company's growth.
• Despite the default, the Company anticipates continuing its collaboration with the noteholder.

Industry Context

The company operates in the biotechnology and life sciences industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition.

Comparison to Industry Standards

• It is difficult to compare Vicapsys Life Sciences to industry standards due to its early stage of development and lack of revenue.
• Many early-stage biotech companies face similar challenges in securing funding and navigating the regulatory landscape.
• Companies like Celldex Therapeutics and Immunomedics, while more advanced, have also experienced periods of financial uncertainty during their development phases.

Legal Proceedings

• The Company is not aware of any material, existing or pending legal proceedings against the Company, nor is it involved as a plaintiff in any material proceeding or pending litigation.

Related Party Transactions

• The company has consulting agreements with related parties, including Mark Poznansky, Donohoe Advisory Associates, LLC, and Alpha IR Group, LLC.
• The company has an MGH License Agreement with a principal stockholder.
• The company incurred director fees to Federico Pier, the Company's Chief Executive Officer and Chairman of the Board.
• The company incurred consulting fees to Jeff Wright, the Company's Chief Financial Officer.
• The company has accrued salaries to Frances Tonneguzzo, the Company's former Chief Executive Officer.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional capital through equity offerings.
• Employees face uncertainty due to the company's going concern issues.
• The company's ability to develop and commercialize its products could be impacted by its financial challenges.
• Creditors face the risk of non-payment if the company is unable to raise additional funding.

Next Steps

• The company intends to raise an additional $1 million to sustain base operations.
• The company will continue to develop its intellectual property rights related to encapsulated products.
• The company will pursue corporate partnerships to advance clinical development and commercialization.
• The company intends to honor the notes and all liabilities as it perseveres in its mission to raise funds for the Company's growth.

Key Dates